


L1 HAS NO ANSWERS

L1 STR



REP G1=(0-1) CH

REP G2=(0-2) CH

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 14 1 8

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> d his 13


(FILE 'REGISTRY' ENTERED AT 15:14:06 ON 16 APR 2008)

L3 597 S L1 FUL

=> d 14

L4 HAS NO ANSWERS

L4 STR



REP G1=(0-1) CH

REP G2=(0-2) CH

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 14 1 8

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

```
ENTER SUBSET L# OR (END):ful
FUL IS NOT A VALID L#
L-numbers must be in the range L1-L999.
ENTER SUBSET L# OR (END):13
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 15:18:54 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 597 TO ITERATE
```


```
100.0% PROCESSED 597 ITERATIONS 466 ANSWERS
SEARCH TIME: 00.00.01
```

```
L5 466 SEA SUB=L3 SSS FUL L4
```

```
=> d scan
```

```
L5 466 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3(2H)-Pyridazinone, 6-[(3S,4S)-3-(5-chloro-2-pyridinyl)-4-[(3R,5S)-4-
hydroxy-3,5-dimethyl-4-phenyl-1-piperidinyl]carbonyl]-1-pyrrolidinyl]-
MF C27 H30 Cl N5 O3
```

```
Absolute stereochemistry.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0
```

```
=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 224.14 224.35
```

```
FILE 'CAPLUS' ENTERED AT 15:19:26 ON 16 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16  
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15  
L6 15 L5  
=> d bib abs 1-15

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:966651 CAPLUS  
DN 147:322997  
TI Preparation of piperidinoylazinylpyrrolidines as melanocortin type 4 receptor agonists  
IN Andrews, Mark David; Brown, Alan Daniel; Lansdell, Mark Ian; Summerhill, Nicholas William  
PA Pfizer Limited, UK  
SO PCT Int. Appl., 71pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007096763	A2	20070830	WO 2007-IB456	20070219
WO 2007096763	A3	20071018		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI US 2006-776295P	P	20060223		
US 2007-887840P	P	20070202		
OS MARPAT 147:322997				
GI				



AB Title compds. [I; 1 of X, Y = N, the other = CH; R = F, Cl, cyano, CF<sub>3</sub>, MeO; R<sub>1</sub> = (substituted) Ph, 2-pyridyl, cycloalkyl, cycloalkylmethyl; R<sub>2</sub> = H, F, Cl; Het = (substituted) 6-membered (aromatic) ring containing 1-2 N atoms; with provisos], were prepared Thus, 2-chloro-5-cyanopyridine, (3R,4R,5S)-1-[(3S,4S)-4-(5-chloropyridin-2-yl)pyrrolidin-3-yl]carbonyl]-4-(4-fluorophenyl)-3,5-dimethylpiperidin-4-ol (preparation given), and ethyldiisopropylamine were heated together in MeCN at 70° overnight to give 77% 6-[(3S,4S)-3-(5-chloropyridin-2-yl)-4-[(3R,4R,5S)-4-(4-fluorophenyl)-4-hydroxy-3,5-dimethylpiperidin-1-yl]carbonyl]pyrrolidin-1-yl]nicotinonitrile. The latter showed MC4 agonist activity with EC<sub>50</sub> <0.52 nM.

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:150961 CAPLUS

DN 146:229190

TI Preparation of pyrrolidinylcarbonylpiperidines as melanocortin subtype 4 (MC4) receptor agonists for treatment of lower urinary tract dysfunction.  
IN McMurray, Gordon; Phillips, Stephen Charles; Westbrook, Simon Lempriere  
PA Pfizer Limited, UK  
SO PCT Int. Appl., 85pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007015157	A2	20070208	WO 2006-IB2119	20060720
	WO 2007015157	A3	20070518		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2615209	A1	20070208	CA 2006-2615209	20060720
PRAI	GB 2005-15817	A	20050801		
	US 2005-705237P	P	20050802		
	WO 2006-IB2119	W	20060720		
OS	MARPAT 146:229190				
GI					



\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I ( $n = 1, 2$ ; R<sub>6</sub> = H, alkyl, cycloalkyl, etc.; R<sub>7</sub> = pyridinyl or Ph (wherein pyridinyl or Ph is optionally substituted by halo, CN, CF<sub>3</sub>, etc.); R<sub>10</sub> = Q<sub>1</sub>; R<sub>1</sub>, R<sub>4</sub> = H, alkyl, OH, etc.; R<sub>2</sub> = H, OH, O-alkyl, etc.; R<sub>3</sub> = aryl or heteroaryl (wherein said moieties are optionally substituted by halo, CN, CF<sub>3</sub>, etc.); R<sub>5</sub> = H or alkyl; R<sub>1</sub>, R<sub>4</sub> and R<sub>5</sub> are not all simultaneously H; when R<sub>1</sub> is Me and R<sub>4</sub> is H, then R<sub>5</sub> is not Me.; when R<sub>4</sub> is Me and R<sub>5</sub> is H, then R<sub>1</sub> is not Me.; when R<sub>5</sub> is Me and R<sub>4</sub> is H, then R<sub>1</sub> is not Me.], pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof were prepared. For example, amidation of (3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid hydrochloride, e.g., prepared from (E)-2,4-difluorocinnamic acid in 3 steps, with (3S,4R)-3-methyl-4-phenylpiperidin-4-ol followed by treatment with HCl afforded compound II-HCl. Compds. according to the invention herein exhibited a binding constant at the MC<sub>4</sub> (melanocortin receptor 4) expressed as an Ki value against AGRP (agouti related protein) lower than 1000 nM. Compds. I are claimed useful for the treatment of sexual dysfunction and obesity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:14419 CAPLUS  
DN 146:121832  
TI Preparation of pyrrolidinylcarbonylpiperidine derivative as MC4R agonist and of crystalline forms of said derivative  
IN Calabria, Ralph; Cheng, Yu; Ferlita, Russell R.; Kamali, Ashkan; Murry, Jerry A.; Mathre, David; Peresypkin, Andrey V.; Thompson, Karen; Wang, Jian; Wenslow, Robert M.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 50pp.  
CODEN: PIXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007002462	A2	20070104	WO 2006-US24573	20060623
	WO 2007002462	A3	20070614		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRAI US 2005-694488P P 20050627

GI




PI WO 2006041769 A2 20060420 WO 2005-US35449 20050930  
 WO 2006041769 A3 20070614  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
 YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
 EP 1804798 A2 20070711 EP 2005-812168 20050930  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU  
 US 2008021067 A1 20080124 US 2007-662018 20070305  
 PRAI US 2004-616064P P 20041005  
 WO 2005-US35449 W 20050930  
 OS MARPAT 144:382018  
 AB The present invention relates to methods of treating and preventing substance addiction and substance abuse, including nicotine addiction and nicotine addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing substance addiction and substance addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compns. and medicaments useful in carrying out these methods.

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:317218 CAPLUS  
 DN 144:363116  
 TI Combination therapy comprising PYY agonists for the treatment of obesity  
 IN Amatruda, John M.; Daruwala, Paul; Erondu, Ngozi E.; Macneil, Douglas J.;  
 Moller, David E.; Qian, Su  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036770	A2	20060406	WO 2005-US34096	20050922
	WO 2006036770	A3	20060817		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005289710	A1	20060406	AU 2005-289710	20050922

CA 2577821	A1	20060406	CA 2005-2577821	20050922
EP 1799241	A2	20070627	EP 2005-803387	20050922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101027075	A	20070829	CN 2005-80032222	20050922
US 20080064632	A1	20080313	US 2007-661960	20070302
IN 2007CN01330	A	20070831	IN 2007-CN1330	20070330
PRAI US 2004-612657/P	P	20040924		
WO 2005-US34096	W	20050922		
OS MARPAT 144:363116				
GI				



AB The present invention relates to compns. comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. One example is a *in vivo* study of the effect of PYY3-36 on 4 h and 16 h food intake and body weight gain in mice and another example is an *in vivo* study of the effect of the combination of PYY3-36 and CB-1 inverse agonist AM-251 (I) on food intake and body weight in mice.

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2006:236714 CAPLUS

DN 144:287793

TI Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists

IN Bristow, Linda; Fong, Tung M.; Morse, Andrew C.; Ren, Kunkun

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006028631	A2	20060316	WO 2005-US28128	20050809
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,		

ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

EP 1781283 A2 20070509 EP 2005-812403 20050809  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU

US 20080085885 A1 20080410 US 2007-660117 20070212  
 PRAI US 2004-601486P P 20040813  
 WO 2005-US28128 W 20050809

OS MARPAT 144:287793

AB The present invention relates to methods of inhibiting or reducing voluntary alc. consumption in a subject comprising administering a non-peptidyl melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing alcoholism, alc. abuse, and alc. related disorders in a subject comprising administering a non-peptidyl melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compns. and medicaments useful in carrying out these methods.

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:165649 CAPLUS

DN 144:232924

TI Preparation of piperidine derivatives as melanocortin-4 receptor agonists  
 IN Barakat, Khaled J.; Guo, Liangqin; Liu, Jian; Nargund, Ravi P.; Sebhate,

PA Iyassu K.; Ye, Zhixiong

SO Merck & Co., Inc., USA

PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006019787	A2	20060223	WO 2005-US24806	20050713
WO 2006019787	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005275232	A1	20060223	AU 2005-275232	20050713
CA 2573714	A1	20060223	CA 2005-2573714	20050713
EP 1773347	A2	20070418	EP 2005-769526	20050713
CN 1984662	A	20070620	CN 2005-80024053	20050713
JP 20080506696	T	20080306	JP 2007-521596	20050713
IN 2006CN04795	A	20071005	IN 2006-CN4795	20061229
US 20080051430	A1	20080228	US 2007-632001	20070109
PRAI US 2004-588494P	P	20040716		
WO 2005-US24806	W	20050713		
OS MARPAT 144:232924				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title piperidine derivs. I [wherein m = 0-2; n = 1-2; R1 and R2 = independently halo, CF3, CH3, and OMe; R3 and R4 = independently halo, CF3, CN, alkyl, alkoxy, etc.; R5 = OH, halo, alkyl, alkoxy, etc.], or pharmaceutically acceptable salts thereof were prepared as agonists of the human melanocortin-4 receptors (MCR-4). For example, II was prepared in a multi-step synthesis. The title compds. showed IC50 less than 10  $\mu$ M against MCR-4. Formulations with finely divided lactose as hard gelatin capsule have been described. The compds. are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MCR-4, such as obesity, diabetes, male or female sexual dysfunction.

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:735328 CAPLUS  
 DN 143:211844  
 TI Preparation of Pyrroolidinyl(carbonyl) piperidines as melanocortin receptor 4 agonists for therapeutic use

IN Calabrese, Andrew Antony; Fradet, David Sebastien; Hepworth, David;

LA Lansdell, Mark

PA Pfizer Inc, UK

SO U.S. Pat. Appl. Publ., 102 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050176772	A1	20050811	US 2005-51144	20050203
AU 2005213538	A1	20050825	AU 2005-213538	20050126
CA 2555800	A1	20050825	CA 2005-2555800	20050126
WO 2005077935	A1	20050825	WO 2005-IB208	20050126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
BN, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1716135	A1	20061102	EP 2005-702363	20050126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1930146	A	20070314	CN 2005-80007573	20050126
BR 2005007435	A	20070703	BR 2005-7435	20050126
JP 2007534668	T	20071129	JP 2006-551945	20050126
JP 4031814	B2	20080109		
NL 1028193	A1	20050808	NL 2005-1028193	20050204
NL 1028193	C2	20060420		
IN 2006DN04212	A	20070622	IN 2006-DN4212	20060721
MX 2006PA08934	A	20061102	MX 2006-PA8934	20060804

NO 2006003944	A	20061031	NO 2006-3944	20060904
PRAI GB 2004-2492	A	20040204		
US 2004-543950P	P	20040212		
GB 2004-12417	A	20040603		
US 2004-580209P	P	20040615		
GB 2004-25530	A	20041119		
US 2004-634916P	P	20041210		
WO 2005-IB208	W	20050126		
OS MARPAT 143:211844				
GI				



AB The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined below and especially to selective MCR4 agonist compds., to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates

used in such processes. The variables for I are: R1 = optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R2 is H, OH or OCH3; R3 = H, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH<sub>2</sub>)<sub>p</sub>R<sub>6</sub>, (CH<sub>2</sub>)<sub>p</sub>NR<sub>7</sub>R<sub>8</sub>, CN, C(O)R<sub>6</sub>, C(O)OR<sub>6</sub>, C(O)NR<sub>7</sub>R<sub>8</sub>, (CH<sub>2</sub>)<sub>p</sub>NR<sub>7</sub>SO<sub>2</sub>R<sub>8</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub> or OCH<sub>2</sub>CF<sub>3</sub> wherein p=0, 1 or 2; R5 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH<sub>2</sub>)<sub>p</sub>R<sub>6</sub>, (CH<sub>2</sub>)<sub>p</sub>NR<sub>7</sub>R<sub>8</sub>, CN, C(O)R<sub>6</sub>, C(O)OR<sub>6</sub>, C(O)NR<sub>7</sub>R<sub>8</sub>, (CH<sub>2</sub>)<sub>p</sub>NR<sub>7</sub>SO<sub>2</sub>R<sub>8</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub> or OCH<sub>2</sub>CF<sub>3</sub> wherein p=0, 1 or 2; or R4 and R5 form a fused ring; R6, R7 and R8 = H, CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>. Compds. of the present invention are particularly suitable for treating female sexual dysfunction, male erectile dysfunction, obesity and diabetes.

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:99460 CAPLUS

DN 142:197886

TI Preparation of 4-aryl-1-(pyrrolidinylcarbonyl)piperidines as melanocortin-4 receptor agonists

IN Sings, Heather; Ujjainwalla, Feroze

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE


-----

-----

-----

-----

PI	WO 2005009950	A2	20050203	WO 2004-US22911	20040716
	WO 2005009950	A3	20050602		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259717	A1	20050203	AU 2004-259717	20040716
	CA 2532808	A1	20050203	CA 2004-2532808	20040716
	EP 1648457	A2	20060426	EP 2004-778422	20040716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1826116	A	20060830	CN 2004-80021119	20040716
	JP 2006528180	T	20061214	JP 2006-521142	20040716
	US 20060128963	A1	20060615	US 2005-560290	20051212
	IN 2006DN00517	A	20070810	IN 2006-DN517	20060131
PRAI	US 2003-489313P	P	20030722		
	WO 2004-US22911	W	20040716		
OS	CASREACT 142:197886; MARPAT 142:197886				
GI					



AB Title compds. [I; R1 = H, amidino, alkyliminoyl, alkyl,  $(\text{CH}_2)_n\text{Q}$ ; n = 0-3; Q = (substituted) amino, cycloalkyl, Ph, naphthyl, heteroaryl; R2 = (substituted) Ph, naphthyl, heteroaryl; R3 = H, alkyl, halo, CF3, CH2CF3, OCF3, OCH2CF3, NO2, OR6, (substituted)  $(\text{CH}_2)_n\text{Q}$ ; Q1 = Ph, naphthyl, heteroaryl, heterocycloalkyl, cycloalkyl, amino, aminocarbonyl, cyano, etc.; R4 = (substituted)  $(\text{CH}_2)_n\text{Q}$ ; Q3 = NR5NR5R6, NR5R9, NR5CO( $\text{CH}_2$ )nCR5[N(R5)2]( $\text{CH}_2$ )nNR5R6, etc.; q = 0-4; R5 = H, (substituted) alkyl, alkylcarbonyl; R6 = R5,  $(\text{CH}_2)_n\text{Q}$ ; Q4 = (substituted) cycloalkyl, heterocycloalkyl, Ph, naphthyl, heteroaryl, bicycloalkyl; R9 = specified amino acid residue; Z = N, CR1; p = 1, 2; m = 0-2], were claimed. Representative I bound to melanocortin-4 receptors with EC50 = 10  $\mu\text{M}$ .

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:80448 CAPLUS

DN 140:122817

TI NPY5 antagonist-antibesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders

IN Macneil, Douglas J.; McIntyre, James H.; Van Der Ploeg, Leonardus H. T.; Ishihara, Akane

PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.

SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009015	A2	20040129	WO 2003-US22077	20030714
	WO 2004009015	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2492225	A1	20040129	CA 2003-2492225	20030714
AU	2003253925	A1	20040209	AU 2003-253925	20030714
EP	1534074	A2	20050601	EP 2003-765587	20030714
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2005533849	T	20051110	JP 2004-523149	20030714
US	20050288213	A1	20051229	US 2005-520566	20050107
PRAI	US 2002-396603P	P	20020718		
	US 2002-417999P	P	20021011		
	WO 2003-US22077	W	20030714		

OS MARPAT 140:122817

AB The invention discloses compns. comprising a NPY5 antagonist and an antiobesity agent, useful for the treatment and prevention of diabetes, obesity, and obesity-related disorders. The invention also discloses methods of treating or preventing obesity and obesity-related disorders in a subject in need thereof by administering a composition of the invention. The invention further discloses pharmaceutical compns., medicaments, and kits useful in carrying out the methods.

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2003:737505 CAPLUS

DN 139:255308

TI Agouti-related protein as biomarker for efficacy of appetite suppressant drugs

IN Fong, Tung M.; Shen, Chun-Pyn; Van der Ploeg, Leonardus H. T.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075742	A2	20030918	WO 2003-US6437	20030303
	WO 2003075742	A3	20040401		
W:	CA, JP, US				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA	2477614	A1	20030918	CA 2003-2477614	20030303
EP	1483580	A2	20041208	EP 2003-711370	20030303
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US	20050169839	A1	20050804	US 2004-506577	20040902

PRAI US 2002-361806P P 20020305  
WO 2003-US6437 W 20030303

AB The present invention relates to agouti-related protein (AGRP) as a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for

the treatment of obesity, wherein the test compound is an appetite suppressant which does not stimulate the release of serotonin. It also relates to a method for following the progress of a therapeutic regime designed to alleviate obesity and to a method for determining the appropriate dosage of an appetite suppressant given to a subject for the treatment of obesity. Plasma levels of AGRP in lean rats were measured by RIA after treatment with various appetite suppressants. AGRP plasma levels were reduced by AM251, a cannabinoid CB1 inverse agonist, and by sibutramine.

L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:675993 CAPLUS

DN 137:216874

TI Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses

IN Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Nyvrott, Matthew J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068388	A2	20020906	WO 2002-US5724	20020225
	WO 2002068388	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2439152	A1	20020906	CA 2002-2439152	20020225
AU	2002258414	A1	20020912	AU 2002-258414	20020225
EE	200300415	A	20031215	EE 2003-415	20020225
EP	1383501	A2	20040128	EP 2002-728357	20020225
EP	1383501	B1	20070404		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU	2003003376	A2	20040128	HU 2003-3376	20020225
HU	2003003376	A3	20070828		
JP	2004529105	T	20040924	JP 2002-567902	20020225
NZ	527364	A	20041224	NZ 2002-527364	20020225
CN	1633297	A	20050629	CN 2002-805674	20020225
BR	2002007658	A	20051025	BR 2002-7658	20020225
AT	358481	T	20070415	AT 2002-728357	20020225
ES	2283550	T3	20071101	ES 2002-728357	20020225
US	20030225060	A1	20031204	US 2003-356879	20030203
US	6818658	B2	20041116		

ZA 2003006160	A	20040721	ZA 2003-6160	20030808
BG 108132	A	20041230	BG 2003-108132	20030825
IN 2003CN01342	A	20051125	IN 2003-CN1342	20030826
NO 2003003812	A	20031028	NO 2003-3812	20030827
MX 2003PA07785	A	20031208	MX 2003-PA7785	20030827
US 20040266821	A1	20041230	US 2004-894719	20040720
IN 2007CN02320	A	20071012	IN 2007-CN2320	20070529
PRAI US 2001-2/2258P	P	20010228		
US 2001-300118P	P	20010622		
WO 2002-US5724	W	20020225		
US 2003-356897	A3	20030203		
IN 2003-CN1342	A3	20030826		
OS MARPAT 137:216874				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Certain novel 4-substituted N-acylated piperidine derivs., specifically I, are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R) [wherein: p = 1 or 2; q = 0, 1, or 2; n = 0, 1, or 2; R1 = H, amidino, alkylimino, (un)substituted alkyl, (CH2)n-G1 [G1 = (un)substituted cycloalkyl, Ph, naphthyl, or heteroaryl]; R2 = (un)substituted Ph, naphthyl, or heteroaryl; X = alkyl, (CH2)n-G2 [G2 = (un)substituted cycloalkyl, Ph, naphthyl, heteroaryl, heterocyclyl, cyano, CONH2, CO2H, OH, NH2, and various derivs.] where any of (CH2)n may also be substituted; including pharmaceutically acceptable salts]. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Approx. 180 invention compds. I and approx. 25 intermediates were prepared. For instance, (2-bromo-5-chlorophenyl)acetic acid underwent a sequence of Me esterification, coupling with tert-Bu 4-[(trifluoromethyl)sulfonyl]oxy]-3,6-dihydropyridine-1(2H)-carboxylate via a boronate ester, removal of the BOC group, and amidation with (3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid. The unsatd. amide-ester underwent hydrogenation, saponification of the ester, and amidation with MeNH2.HCl, to give title compound II. Representative compds. I bound to cloned human MC-4R in vitro with IC50 values generally below 2  $\mu$ M, and also acted as agonists toward cloned human MCR in a functional assay with EC50 values less than 1  $\mu$ M.

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1999:172595 CAPLUS  
 DN 130:223167

TI Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity


IN Budhu, Richard J.; Hale, Jeffrey J.; Holson, Edward; Lynch, Christopher; MacCoss, Malcolm; Mills, Sander G.; Berk, Scott C.; Willoughby, Christopher A.

PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 262 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

PI WO 9909984 A1 19990304 WO 1998-US17755 19980827  
 W: AI, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR,  
 HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK,  
 MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA,  
 US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2298813 A1 19990304 CA 1998-2298813 19980827  
 AU 9892067 A 19990316 AU 1998-92067 19980827  
 EP 1009405 A1 20000621 EP 1998-944548 19980827  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 SI, LT, LV, FI, RO  
 US 6166037 A 20001226 US 1998-141227 19980827  
 JP 2001526178 T 20011218 JP 2000-507374 19980827  
 PRAI US 1997-57743P P 19970828  
 GB 1998-1009 A 19980116  
 WO 1998-US17755 W 19980827  
 OS MARPAT 130:223167  
 GI



AB Title modulators [I; R1 = CH2Ph, SO2Ph, CONHPh, H, COPh, (CH2)3Ph,  
 1-fluorenecarbonyl, etc.; R = OH, H, Ph, CF3, CH2Ph, etc.; n = 0-2; S = S,  
 C; R2 = benzo[d]azepin-3-yl, 4-phenyl-perhydroazepin-1-yl, etc.],  
 pharmaceutically acceptable salts thereof, individual diastereomers, and  
 enantiomers thereof are prepared as modulators of chemokine receptor  
 activity. 21X19 combinatorial library was mentioned using com. available  
 4-sulfonylbenzoyl polystyrene resin supported subunits (21 pools) of  
 trifluoromethylsulfonyl chloride, arylsulfonyl(carbonyl) chlorides, and  
 heterocyclic sulfonyl(carbonyl) chlorides. Thus, compound II was prepared  
 from Me (Z)-cinnamate and N-(methoxymethyl)-N-  
 (trimethylsilylmethyl)benzylamine via seven steps.

RE.CNT 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 13-15


L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
IT 455956-46-4

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(melanocortin receptor 4 agonist, plasma AGRP levels in lean rats after  
treatment with; agouti-related protein as biomarker for efficacy of  
appetite suppressant drugs)

RN 455956-46-4 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-  
pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
IT 455956-36-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of acylated piperidine derivs., particularly  
(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines,  
and analogs, as melanocortin-4 receptor agonists)

RN 455956-36-2 CAPLUS

CN Benzenesacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-  
dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-, methyl ester (CA  
INDEX NAME)

Absolute stereochemistry.



IT 455955-95-0P 455955-96-1P 455955-97-2P

455955-98-3P 455955-99-4P 455956-00-0P  
455956-01-1P 455956-02-2P 455956-03-3P  
455956-04-4P 455956-05-5P 455956-06-6P  
455956-07-7P 455956-08-8P 455956-09-9P  
455956-10-2P 455956-11-3P 455956-12-4P  
455956-13-5P 455956-14-6P 455956-15-7P  
455956-16-8P 455956-17-9P 455956-18-0P  
455956-19-1P 455956-20-4P 455956-21-5P  
455956-22-6P 455956-23-7P 455956-24-8P  
455956-25-9P 455956-26-0P 455956-27-1P  
455956-28-2P 455956-29-3P 455956-30-6P  
455956-31-7P 455956-32-8P 455956-33-9P  
455956-34-0P 455956-35-1P 455956-37-3P  
455956-38-4P 455956-39-5P 455956-40-8P  
455956-41-9P 455956-42-0P 455956-43-1P  
455956-44-2P 455956-45-3P 455956-46-4P  
455956-47-5P 455956-48-6P 455956-49-7P  
455956-50-0P 455956-51-1P 455956-52-2P  
455956-53-3P 455956-54-4P 455956-55-5P  
455956-56-6P 455956-57-7P 455956-58-8P  
455956-59-9P 455956-60-2P 455956-61-3P  
455956-62-4P 455956-63-5P 455956-64-6P  
455956-65-7P 455956-66-8P 455956-67-9P  
455956-68-0P 455956-69-1P 455956-70-4P  
455956-71-5P 455956-72-6P 455956-73-7P  
455956-74-8P 455956-75-9P 455956-76-0P  
455956-77-1P 455956-78-2P 455956-79-3P  
455956-80-6P 455956-81-7P 455956-82-8P  
455956-83-9P 455956-84-0P 455956-85-1P  
455956-86-2P 455956-87-3P 455956-88-4P  
455956-89-5P 455956-90-8P 455956-91-9P  
455956-92-0P 455956-93-1P 455956-94-2P  
455956-95-3P 455956-96-4P 455956-97-5P  
455956-98-6P 455956-99-7P 455957-00-3P  
455957-01-4P 455957-02-5P 455957-03-6P  
455957-04-7P 455957-05-8P 455957-06-9P  
455957-07-0P 455957-08-1P 455957-09-2P  
455957-10-5P 455957-11-6P 455957-12-7P  
455957-13-8P 455957-14-9P 455957-15-0P  
455957-16-1P 455957-17-2P 455957-18-3P  
455957-19-4P 455957-20-7P 455957-21-8P  
455957-22-9P 455957-23-0P 455957-24-1P  
455957-25-2P 455957-26-3P 455957-27-4P  
455957-28-5P 455957-29-6P 455957-30-9P  
455957-31-0P 455957-32-1P 455957-33-2P  
455957-34-3P 455957-35-4P 455957-36-5P  
455957-37-6P 455957-38-7P 455957-39-8P  
455957-40-1P 455957-41-2P 455957-42-3P  
455957-43-4P 455957-44-5P 455957-45-6P  
455957-46-7P 455957-47-8P 455957-48-9P  
455957-49-0P 455957-50-3P 455957-51-4P  
455957-52-5P 455957-53-6P 455957-54-7P  
455957-55-8P 455957-56-9P 455957-57-0P  
455957-58-1P 455957-59-2P 455957-60-5P  
455957-61-6P 455957-65-0P 455957-66-1P  
455957-67-2P 455957-68-3P 455957-69-4P  
455957-70-7P 455957-71-8P 457068-69-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of acylated piperidine derivs., particularly

(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)

RN 455955-95-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-96-1 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-97-2 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-98-3 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-pyrrolidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-99-4 CAPLUS

CN Benzanide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-00-0 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-01-1 CAPLUS

CN Benzanide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl- (CA INDEX NAME)


## Absolute stereochemistry.



RN 455956-02-2 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


### Absolute stereochemistry.



RN 455956-03-3 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-propyl- (CA INDEX NAME)


### Absolute stereochemistry.



RN 455956-04-4 CAPLUS


CN Piperidine, 4-[2-(1-azetidinylcarbonyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 455956-05-5 CAPLUS  
 CN Benzamide, 2-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-06-6 CAPLUS  
 CN Piperidine, 4-(2-cyano-4-fluorophenyl)-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-07-7 CAPLUS  
 CN Benzamide, 5-chloro-2-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-08-8 CAPLUS

CN Benzamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-09-9 CAPLUS

CN Benzenesacetic acid, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-10-2 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-11-3 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-12-4 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-13-5 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-14-6 CAPLUS

CN Benzeneacetamide, N-cyclobutyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-15-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidinyl)-2-oxoethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-16-8 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-17-9 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-18-0 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-19-1 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-20-4 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-21-5 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-22-6 CAPLUS


CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-propyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-23-7 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-24-8 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-25-9 CAPLUS  
 CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-26-0 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-27-1 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-28-2 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-29-3 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl-N-methyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455956-30-6 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl-N-(1-methylethyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455956-31-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidinyl)-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-32-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-33-9 CAPLUS

CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-34-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-35-1 CAPLUS

CN Benzoic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-37-3 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(dimethylamino)sulfonyl]phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-38-4 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4-fluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-39-5 CAPLUS

CN Benzoic acid, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-6-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-40-8 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-41-9 CAPLUS


CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-42-0 CAPLUS  
 CN Benzoic acid, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-43-1 CAPLUS  
 CN Benzanide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-44-2 CAPLUS  
 CN Benzoic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-45-3 CAPLUS  
 CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-46-4 CAPLUS  
 CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-5-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-47-5 CAPLUS  
 CN Benzamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-48-6 CAPLUS

CN Benzanide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-49-7 CAPLUS

CN Benzanide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-50-0 CAPLUS


CN Benzanide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-51-1 CAPLUS  
 CN Piperidine, 4-[2-(1-azetidinylcarbonyl)-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-52-2 CAPLUS  
 CN Benzanide, 5-chloro-N-cyclopropyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-53-3 CAPLUS  
 CN Benzanide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-4,5-difluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-54-4 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorobenzoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-55-5 CAPLUS


CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-56-6 CAPLUS  
 CN Piperidine, 4-[2-[2-(1-azetidinyl)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-57-7 CAPLUS  
 CN Piperidine, 4-[2-[2-(1-azetidinyl)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 455956-56-6  
 CMF C32 H40 Cl F2 N3 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 455956-58-8 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N, $\alpha$ -dimethyl-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 455956-59-9 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- $\alpha$ -methyl-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 455956-60-2 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ -methyl-N-propyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455956-61-3 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ -methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-62-4 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1,1-dimethylethyl)- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-63-5 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-64-6 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-65-7 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopentyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-66-8 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclohexyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-

piperidinyl]- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-67-9 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N, $\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-68-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N,N-diethyl- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-69-1 CAPLUS

CN Benzenacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl- $\alpha$ -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-70-4 CAPLUS

CN Benzenacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N, $\alpha$ -dimethyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-71-5 CAPLUS

CN Benzenacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-(1,1-dimethylethyl)-N, $\alpha$ -dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-72-6 CAPLUS

CN Piperidine, 4-[4-chloro-2-(1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl-

1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-73-7 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-methyl-2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-74-8 CAPLUS

CN 1-Propanone, 1-(1-azetidinyl)-2-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-75-9 CAPLUS

CN Piperidine, 4-[2-[(1R)-2-(1-azetidinyl)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-76-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ , $\alpha$ -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-77-1 CAPLUS

CN Benzeneacetic acid, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ , $\alpha$ -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-78-2 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ , $\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-79-3 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidinyl)-1,1-dimethyl-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-80-6 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidinyl)-1,1-dimethyl-2-oxoethyl]-4-fluorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-81-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidinyl)-1,1-dimethyl-2-oxoethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-82-8 CAPLUS

CN Piperidine, 4-[2-[1-(1-azetidinylcarbonyl)cyclopropyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-83-9 CAPLUS

CN Cyclopropanecarboxamide, 1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-84-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-85-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-(1-hydroxy-1-methylethyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-86-2 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-α,α-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-87-3 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-4-fluoro-N,α,α-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-88-4 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-5-fluoro-N-(2-hydroxyethyl)-N,α,α-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-89-5 CAPLUS

CN Morpholine, 4-[2-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-2-methyl-1-oxopropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-90-8 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha,\alpha$ -dimethyl-, hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-91-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha,\alpha$ -dimethyl-, 2-(1-methylethyl)hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-92-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ , $\alpha$ -dimethyl-, 2-acetylhydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-93-1 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-94-2 CAPLUS

CN Piperidine, 4-(2-aminophenyl)-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-95-3 CAPLUS

CN Proacetamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-96-4 CAPLUS

CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-97-5 CAPLUS


CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-98-6 CAPLUS  
 CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2,2-dimethyl-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-99-7 CAPLUS  
 CN Cyclohexanecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-00-3 CAPLUS  
 CN Butanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-01-4 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-02-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-03-6 CAPLUS


CN Benzanide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-04-7 CAPLUS  
 CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[(methylsulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-05-8 CAPLUS  
 CN Piperidine, 4-[2-(aminomethyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-06-9 CAPLUS  
 CN Piperidine, 4-[2-[(diethylamino)carbonyl]amino]methylphenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-07-0 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[(methyl(1-methylethyl)amino)carbonyl]amino]methylphenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-08-1 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[(methylamino)carbonyl]amino]methylphenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-09-2 CAPLUS


CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[(dimethylamino)carbonyl]amino]methylphenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-10-5 CAPLUS  
 CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[2-[(1,1-dimethylethyl)amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-11-6 CAPLUS  
 CN Acetanide, N-[(2-[(1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-12-7 CAPLUS  
 CN Propanamide, N-[(2-[(1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-13-8 CAPLUS  
 CN Propanamide, N-[(2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl)phenyl]methyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-14-9 CAPLUS  
 CN Propanamide, N-[(2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl)phenyl]methyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-15-0 CAPLUS  
 CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(4,4-dimethyl-2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-16-1 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-17-2 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(2-oxo-3-oxazolidinyl)ethyl]phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-18-3 CAPLUS

CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-19-4 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-20-7 CAPLUS

CN 1,2,5-Thiadiazole-3-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-21-8 CAPLUS

CN 4-Oxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-22-9 CAPLUS

CN 5-Oxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-23-0 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-24-1 CAPLUS

CN 4-Isoxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-25-2 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-26-3 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-27-4 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-28-5 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-29-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-30-9 CAPLUS

CN Acetamide, N-[(1R)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-31-0 CAPLUS

CN Cyclobutanecarboxamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl] - (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-32-1 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl] - (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-33-2 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-2-methyl - (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-34-3 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-35-4 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[(methylamino)carbonyl]amino]ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-36-5 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[(1,1-dimethylethyl)amino]carbonyl]amino]ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-37-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-38-7 CAPLUS

CN Acetanide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-39-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-(5-oxo-3-pyrrolidinyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-40-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-(5-oxo-2-pyrrolidinyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-41-2 CAPLUS

CN Acetamide, N-[1-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-42-3 CAPLUS

CN Acetamide, N-[1-[2-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-43-4 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-44-5 CAPLUS

CN Acetamide, N-[(1S)-1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-ethylphenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-45-6 CAPLUS

CN Piperidine, 4-[2-[(1S)-1-aminoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-46-7 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-47-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-48-9 CAPLUS

CN 1H-Imidazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-49-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-50-3 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-51-4 CAPLUS


CN Piperidine, 4-[4-chloro-2-[1-(methylamino)ethyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-52-5 CAPLUS  
 CN Piperidine, 4-[4-chloro-2-[(2S)-5-oxo-2-pyrrolidinyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-53-6 CAPLUS  
 CN Piperidine, 4-[4-chloro-2-[(2R)-5-oxo-2-pyrrolidinyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-54-7 CAPLUS  
 CN Piperidine, 4-[4-chloro-2-(2-oxo-5-oxazolidinyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



BN 455957-55-8 CAPIUS

CN Piperidine, 4-[(4-chloro-2-(6-oxo-2-piperidinyl)phenyl)-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


### Absolute stereochemistry.



BN 455957-56-9 CAPIUS

CN Piperidine, 4-[(4-chloro-2-[(3R)-2-oxo-3-pyrrolidinyl]phenyl)-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


### Absolute stereochemistry.



BN 455957-57-0 CAPIUS


AN 453551-37-0 CARLOS  
CN Piperidine, 4-[4-chloro-2-[(3S)-2-oxo-3-pyrrolidinyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME).

### Absolute stereochemistry.




RN 455957-58-1 CAPLUS  
 CN Piperidine, 4-[4-chloro-2-[(4R)-2-oxo-4-oxazolidinyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-59-2 CAPLUS  
 CN Piperidine, 4-[4-chloro-2-[(4S)-2-oxo-4-oxazolidinyl]phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-60-5 CAPLUS  
 CN Acetamide, N-[(1R)-1-{2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl}-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-61-6 CAPLUS

CN Acetanide, N-[(1S)-1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-65-0 CAPLUS

CN Benzamide, 5-chloro-2-[1-[(3R,4S)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-66-1 CAPLUS

CN Piperidine, 4-[2-[1-(1-azetidinylcarbonyl)cyclopropyl]-4-fluorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-67-2 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-1-methylethyl- (CA INDEX NAME)


### Absolute stereochemistry.



RN 455957-68-3 CAPLUS

AN 100-00-0  
CN Piperidine, 1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl-4-[4-fluoro-2-[1-[(methylamino)carbonyl]amino]ethyl]phenyl- (9CI) (CA INDEX NAME)


### Absolute stereochemistry.



BN 455957-69-4 CAPLUS


RN 93577-65-4  
 CAS 93577-65-4  
 CN Cylobutantanecarboxamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl- (CA INDEX NAME)

### Absolute stereochemistry.




RN 455957-70-7 CAPLUS  
 CN Propanamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]-(CA INDEX NAME)

Absolute stereochemistry.



RN 455957-71-8 CAPLUS  
 CN Acetanide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 457068-69-8 CAPLUS  
 CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-(CA INDEX NAME)

Absolute stereochemistry.



IT 455957-79-6P 455957-80-9P 455957-84-3P

455957-85-4P 455957-86-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of acylated piperidine derivs., particularly (pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)

RN 455957-79-6 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-80-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-84-3 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl- $\alpha$ -methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-85-4 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ -methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-86-5 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha$ -methyl- (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 221142-59-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221142-59-2 CAPLUS

CN Piperidin, 4-phenyl-1-[(3R,4S)-4-phenyl-1-(phenylmethyl)-3-pyrrolidinyl]carbonyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 221141-75-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221141-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-phenyl-3-[(4-phenyl-1-piperidinyl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

